SAN RAFAEL, Calif.,
Oct. 11, 2017 /PRNewswire/
--
Key program updates will include the following:
- BMN 270 gene therapy for hemophilia A: 4e13 dose and
Phase 3 Study Design
- Vosoritide for achondroplasia: long-term extension
data
- Pegvaliase for phenylketonuria: safety and efficacy data
provided in BLA
- BMN 250 for MPSIIIB: GAG data and clinical data
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D
Day from 8am (ET) to 1pm (ET) on
Wednesday, October 18, 2017 in
New York City. BioMarin management
and external experts will provide an update to the investment
community on the Company's development portfolio, which is focused
on innovative therapies to treat rare and ultra-rare diseases.
External key opinion leaders scheduled to present include:
Maureen Cleary, M.D.,
F.R.C.P.C.H., Consultant in Inherited Metabolic Disease and Senior
Lecturer at Institute of Child Health at Great Ormond Street
Hospital for Children
- Clinical trial investigator on BMN 250 for MPS IIIB
program
Nicola Longo, M.D., Ph.D.,
Professor of Pediatrics and Adjunct Professor of Pathology at the
University of Utah
- Past President of the Society for the Study of Inborn Errors of
Metabolism (SSIEM)
- Clinical trial investigator on pegvaliase program
Steven Pipe, M.D., Pediatric
hematologist; Laurence A. Boxer Research Professor of Pediatrics
and Communicable Disease, as well as Professor of Pathology at the
University of Michigan
- Primary clinical interest is inherited and acquired bleeding
and thrombotic disorders, including hemophilia, von Willebrand
disease, rare coagulation factor deficiencies and
thrombophilias
BioMarin speakers scheduled to present include:
Jean-Jacques Bienaimé, Chairman and Chief Executive Officer
Hank Fuchs, M.D., President,
Worldwide Research & Development
Robert Baffi, Ph.D., Executive Vice
President, Technical Operations
Geoff Nichol, M.B., Ch.B., M.B.A.,
Senior Vice President, Chief Medical Officer and Head of Global
Clinical Development
David Jacoby, M.D., Ph.D., Executive
Group Medical Director
Adam Shaywitz, M.D., Ph.D.,
Executive Medical Director, Clinical Science
Ben Kim, M.D., M.Phil., Senior
Medical Director, BMN 270
Steve Maricich, M.D., Ph.D., Medical
Director, Clinical Science
Live Video Webcast
Interested parties may access a
live video webcast that will include audio and slides of the
presentations via the investor section of the BioMarin
website, www.biomarin.com. A replay of the meeting will be
archived on the site for at least one week.
For those who choose not to listen and view the event via
webcast, dial-in information for the audio portion of the webcast
can be accessed using:
U.S. / Canada Dial-in Number: (800) 319-9003
International Dial-in Number: (719) 325-3302
Conference ID: 138108
About BioMarin
BioMarin is a global biotechnology
company that develops and commercializes innovative therapies for
patients with serious and life-threatening rare and ultra-rare
genetic diseases. The company's portfolio consists of six
commercialized products and multiple clinical and pre-clinical
product candidates. For additional information, please
visit www.biomarin.com. Information on BioMarin's website is
not incorporated by reference into this press release.
Contacts:
|
|
Investors
|
Media
|
Traci
McCarty
|
Debra
Charlesworth
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(415)
455-7451
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-rd-day-on-october-18th-in-new-york-300534607.html
SOURCE BioMarin Pharmaceutical Inc.